On May 1, 2025 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place from May 30 to June 3 in Chicago, IL (Press release, Regeneron, MAY 1, 2025, View Source [SID1234652452]). Eighteen presentations will share the latest insights from ongoing research of approved and investigational treatment regimens across a range of difficult-to-treat cancers including non-melanoma and melanoma skin cancer, lung cancer, lymphoma and multiple myeloma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our broad oncology and hematology programs are uniquely designed to investigate regimens that could provide meaningful impact for people living with difficult-to-treat cancers across all stages of the treatment paradigm," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "Our PD-1 inhibitor Libtayo is the standard of care in advanced cutaneous squamous cell carcinoma, and in clinical trials, our investigational BCMAxCD3 bispecific antibody linvoseltamab has demonstrated a compelling profile in relapsed or refractory multiple myeloma. At ASCO (Free ASCO Whitepaper), our presentations showcase how we are seeking to further transform the treatment of these diseases with updates from two key programs – our Phase 3 trial exploring adjuvant Libtayo in high-risk cutaneous squamous cell carcinoma and early data from investigational combinations of linvoseltamab and different proteasome inhibitors in third-line or higher multiple myeloma."
Notable presentations at ASCO (Free ASCO Whitepaper) on Regeneron’s oncology pipeline include detailed efficacy and safety findings from the Phase 3 C-POST trial evaluating the adjuvant use of the PD-1 inhibitor Libtayo in post-surgical high-risk cutaneous squamous cell carcinoma (CSCC). The results will be presented in an oral session on Saturday, May 31.
In hematology, Regeneron will debut results from two cohorts of the LINKER-MM2 trial, which is exploring combinations of linvoseltamab, Regeneron’s investigational BCMAxCD3 bispecific antibody. These include combinations of linvoseltamab with carfilzomib or bortezomib in relapsed/refractory (R/R) multiple myeloma (MM) after at least two lines of therapy, which will be featured in two rapid oral presentations on Monday, June 2.
In addition, the results of a cooperative group study reporting on the primary analysis of a randomized Phase 2 trial of vidutolimod in combination with an anti-PD-1 versus anti-PD-1 as neoadjuvant therapy in stage 3 resectable melanoma will be presented in an oral session on Tuesday, June 3. Vidutolimod is a toll like receptor 9 antagonist that was acquired by Regeneron in 2022.
The full list of Regeneron presentations at ASCO (Free ASCO Whitepaper) includes:
Medicine Abstract title Abstract and
Session Lead author Presentation
date/time
(all CDT)
Skin Cancer
Libtayo
Phase 3 trial of
adjuvant cemiplimab
(cemi) versus
placebo (pbo) for
high-risk cutaneous
squamous cell
carcinoma (CSCC) #6001
Oral Abstract
Session – Head
and Neck Cancer Danny Rischin Saturday,
May 31
1:15 p.m. –
4:15 p.m.
Libtayo Patient-reported
outcomes (PROs) in
the C-POST trial of
adjuvant cemiplimab
(cemi) vs placebo
(pbo) for high-risk
cutaneous
squamous cell
carcinoma (CSCC) #6065
Poster Session
– Head and
Neck Cancer Annette M. Lim Monday, June
2
9:00 a.m. –
12:00 p.m.
Libtayo CemiplimAb-rwlc
Survivorship and
Epidemiology
(CASE): Interim
results from a
prospective study of
the safety and
effectiveness of
cemiplimab in
patients with
advanced cutaneous
squamous cell
carcinoma (CSCC)
in a real-world
setting #9533
Poster Session
–
Melanoma/Skin
Cancers Soo J. Park Sunday, June
1
9:00 a.m. –
12:00 p.m.
Libtayo A Phase 3
randomized study of
low-dose
intralesional
cemiplimab versus
primary surgery for
patients with early-
stage cutaneous
squamous cell
carcinoma (CLEAR
CSCC) #TPS9612
Poster Session
–
Melanoma/Skin
Cancers Michael Migden Sunday, June
1
9:00 a.m. –
12:00 p.m.
Fianlimab,
Libtayo A randomized phase
2 peri-operative
(neoadjuvant plus
adjuvant) study of
fianlimab (anti–LAG-
3) plus cemiplimab
(anti–PD-1) versus
anti–PD-1 alone in
patients with
resectable stage III
and IV melanoma #TPS9596
Poster Session
–
Melanoma/Skin
Cancers Rodabe N.
Amaria Sunday, June
1
9:00 a.m. –
12:00 p.m.
Libtayo Utilizing EORTC
Item Library to
develop a tailored
patient-reported
outcome measure
(CSCC-NAAP-32) to
evaluate quality of
life in resectable
advanced (RA)
cutaneous
squamous cell
carcinoma (CSCC) #e18014
Publication-
Only Abstract:
Head and Neck
Cancer Neil Gross N/A
Vidutolimod A phase 2
randomized study of
neoadjuvant
pembrolizumab (P)
alone or in
combination with
vidutolimod (V) in
high-risk resectable
melanoma: ECOG-
ACRIN 6194 #LBA9505
Oral Abstract
Session –
Melanoma/Skin
Cancers Ahmad Tarhini Tuesday, June
3
9:45 a.m. –
12:45 p.m.
Multiple Myeloma
Linvoseltamab Linvoseltamab
(LINVO) +
carfilzomib (CFZ) in
patients (pts) with
relapsed/refractory
multiple myeloma
(RRMM): Initial
results from the
LINKER-MM2 trial #7513
Rapid Oral
Abstract Session –
Hematologic
Malignancies—
Plasma Cell
Dyscrasia Salomon Manier Monday, June
2
8:00 a.m. –
9:30 a.m.
Linvoseltamab Linvoseltamab
(LINVO) +
bortezomib (BTZ) in
patients (pts) with
relapsed/refractory
multiple myeloma
(RRMM): First
results from the
LINKER-MM2 trial #7510
Rapid Oral
Abstract
Session –
Hematologic
Malignancies—
Plasma Cell
Dyscrasia Paula
Rodríguez-Otero Monday, June
2
8:00 a.m. –
9:30 a.m.
Linvoseltamab Indirect comparison
of linvoseltamab
versus elranatamab
for triple-class
exposed (TCE)
relapsed/refractory
multiple myeloma
(RRMM) #7531
Poster Session
– Hematologic
Malignancies—
Plasma Cell
Dyscrasia Sundar
Jagannath Sunday, June
1
9:00 a.m. –
12:00 p.m.
Linvoseltamab Second primary
malignancy (SPM) in
patients (pts) with
multiple myeloma
(MM) receiving
chimeric antigen
receptor T-cell (CAR
T) therapy or other
systemic anticancer
therapy (SACT): A
comparative study
using a real-world
database #7519
Poster Session
– Hematologic
Malignancies—
Plasma Cell
Dyscrasia Attaya
Suvannasankha Sunday, June
1
9:00 a.m. –
12:00 p.m.
Linvoseltamab Concordance
between blinded
independent central
review committee
and physician-
assessed
responses: Analyses
based on a real-
world external
control arm in
relapsed/refractory
multiple myeloma
using International
Myeloma Working
Group data #e19521
Publication-
Only Abstract:
Hematologic
Malignancies—
Plasma Cell
Dyscrasia Brian G. Durie N/A
Lung Cancer
REGN7075,
Libtayo A randomized study
of neoadjuvant
REGN7075 +
cemiplimab +
chemotherapy
(chemo) vs
cemiplimab + chemo
in patients (pts) with
resectable non-small
cell lung cancer
(NSCLC) #TPS8116
Poster Session
–Lung
Cancer—Non-
Small Cell
Local-
Regional/Small
Cell/Other
Thoracic
Cancers Ardy Davarifar Saturday,
May 31
1:30 p.m. –
4:30 p.m.
Fianlimab,
Libtayo Phase 2 peri-
operative study of
fianlimab +
cemiplimab +
chemotherapy
versus cemiplimab +
chemotherapy in
resectable early-
stage non-small cell
lung cancer
(NSCLC) #TPS8117
Poster Session
– Lung Cancer
Non-Small Cell
Local-
Regional/Small
Cell/Other
Thoracic
Cancers Ekaterine
Arkania Saturday,
May 31
1:30 p.m. –
4:30 p.m.
Libtayo Evaluation of current
programmed death-
ligand 1 (PD-L1)
testing trends for
metastatic non-small
cell lung cancer
(mNSCLC): Insights
from a large network
of US community
oncology practices #e23294
Publication-
Only Abstract:
Quality
Care/Health
Services
Research Kathleen M.
Aguilar N/A
Libtayo Evaluating the
safety and
effectiveness of
cemiplimab in
combination with
platinum-doublet
chemotherapy by
demographic
characteristics in
first-line treatment of
advanced non-small
cell lung cancer: An
ongoing multi-
database real world
evidence study in
US patients #e20572
Publication-
Only Abstract:
Lung Cancer—
Non-Small Cell
Metastatic Alexi
Archambault N/A
Head and Neck Cancer
Fianlimab,
Libtayo A Phase 2 study of
fianlimab (anti-LAG-
3) plus cemiplimab
(anti-PD-1) versus
cemiplimab plus
placebo in patients
with
recurrent/metastatic
head and neck
squamous cell
carcinoma (HNSCC)
with positive PD-L1
expression #TPS6112
Poster Session
– Head and
Neck Cancer Danny Rischin Monday, June
2
9:00 a.m. –
12:00 p.m.
Lymphoma
Odronextamab Long-term follow-up
of the phase 2 ELM-
2 study:
Odronextamab for
patients (pts) with
relapsed/refractory
(R/R) follicular
lymphoma (FL) #7049
Poster Session –
Hematologic
Malignancies—
Lymphoma and
Chronic
Lymphocytic
Leukemia Deepa
Jagadeesh Sunday, June
1
9:00 a.m. –
12:00 p.m.
Odronextamab Second primary
malignancy in
patients with diffuse
large B-cell
lymphoma (DLBCL)
receiving chimeric
antigen receptor T-
cell (CAR T) therapy
and other systemic
anti-cancer therapy:
A real-world data
analysis #7080
Poster Session
– Hematologic
Malignancies—
Lymphoma and
Chronic
Lymphocytic
Leukemia Matthew
Lunning Sunday, June
1
9:00 a.m. –
12:00 p.m.
The potential uses of Libtayo in adjuvant CSCC, fianlimab, REGN7075, vidutolimod, and the combinations with linvoseltamab described above are investigational, and their safety and efficacy in these uses have not been fully evaluated by any regulatory authority. Fianlimab, REGN7075 and vidutolimod are not currently approved for use in any indication. Odronextamab is conditionally approved as Ordspono in the European Union for the treatment of R/R follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, although its safety and efficacy have not been fully evaluated by any other regulatory authority. Linvoseltamab is conditionally approved as Lynozyfic in the European Union for the treatment of adult patients with R/R multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy, although its safety and efficacy have not been fully evaluated by any other regulatory authority. The U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Applications for linvoseltamab and odronextamab with respective target action dates for FDA decisions of July 10, 2025 and July 30, 2025.